万泰生物：二价HPV疫苗通过WHO PQ周期性复核

Core Viewpoint - Wantai Biological Pharmacy Enterprise (万泰生物) announced that its subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has successfully passed the WHO PQT–INS periodic review for its bivalent HPV vaccine, which will facilitate the company's future expansion into international markets [1] Group 1 - The bivalent HPV vaccine is the first of its kind in China and the fourth globally for the prevention of cervical cancer [1] - The vaccine is primarily intended for women aged 9 to 45 and is designed to prevent cervical cancer caused by high-risk HPV types 16 and 18, as well as related cervical lesions [1] - The vaccine targets various conditions including CIN2/3, AIS, and CIN1, along with persistent infections caused by HPV types 16 and 18 [1]